Article Text

Download PDFPDF

2022-RA-1250-ESGO The MULTISENT study: a multicenter study about the sentinel lymph node biopsy in clinical stage I and II endometrial cancer
Free
  1. Natalia R Gomez-Hidalgo1,
  2. Silvia Cabrera-Diaz1,
  3. Vicente Bebia Conesa1,
  4. Virginia Garcia Pineda2,
  5. Pablo Iserte3,
  6. Francesc Fargas Fabregas4,
  7. Pere Fuste5,
  8. Paula Alonso6,
  9. Tomas Gomez Rodriguez7,
  10. Sergi Fernandez8,
  11. Enrique Chacon9,
  12. Jose Antonio Perez Alvarez10,
  13. Reyes Oliver11,
  14. Fernando Roldan Rivas12,
  15. Anna Torrent13,
  16. Andres Rave14,
  17. Carlos A Lopez de la Manzanara Cano15,
  18. Josep Sanchis Pla16,
  19. Antonio Gil Moreno1,
  20. The MULTISENT STUDY GROUP
  1. 1Gynecology Oncology, Vall d´Hebron University Hospital, Barcelona, Spain
  2. 2Gynecology Oncology, La Paz Uniervsity Hospital, Madrid, Spain
  3. 3Gynecology Oncology, La Fe University Hospital, Valencia, Spain
  4. 4Gynecology Oncology, Dexeus Hospital, Barcelona, Spain
  5. 5Gynecology Oncology, Clinic Hospital, Barcelona, Spain
  6. 6Gynecology Oncology, Gregorio Marañon University Hospital, Madrid, Spain
  7. 7Gynecology Oncology, Virgen de la Victoria Hospital, Malaga, Spain
  8. 8Gynecology Oncology, Bellvitge Hospital, Barcelona, Spain
  9. 9Gynecology Oncology, University Clinic of Navarra, Pamplona, Spain
  10. 10Gynecology Oncology, Nuestra Señora de la Candelaria Hospital, Santa Cruz de Tenerife, Spain
  11. 11Gynecology Oncology, 12 de Octubre University Hospital, Madrid, Spain
  12. 12Gyneology Oncology, University Clinic Hospital of Zaragoza, Zaragoza, Spain
  13. 13Gynecology Oncology, University Hospital of Son Espases, Mallorca, Spain
  14. 14Gynecology Oncology, University Hospital Dr Negrin Gran Canarias, Gran Canarias, Spain
  15. 15General University Hospital of Ciudad Real, Ciudad Real, Spain
  16. 16IVO, Valencia, Spain

Abstract

Introduction/Background To evaluate the most accurate technique for sentinel-lymph-node (SLN) biopsy in Endometrial cancer (EC) performed by the different Spanish centers.

Methodology This is a multi-institutional retrospective study including patients with preoperative clinical stage I-II EC FIGO 2009, of all histologies and grades undergoing SLN mapping from January 2015 to January 2022. Patients received three different tracers: Indocyanine green (ICG), ICG + technetium-99m (99mTC) and 99mTC alone and different sites of injections (cervical, uterus and both) were used. Twenty-four Spanish centers were enrolled. Negative SLN were ultra-staged with immunohistochemistry for cytokeratin and OSNA.

Results 1221 patients were analyzed. Median number of resected SLNs was 2 (range 1–3). 526 (43%) patients received ICG, 332 (27.1%) received ICG + 99mTC and 363 (29.7%) 99mTC alone. The cervical injection was used in 1121 (92%) patients, 60 (5%) patients underwent a uterine injection and 40 (3%) patients received both. The bilateral mapping rates were 324 (61.6%) for ICG group, 250 (75.3%) for ICG + 99mTC and 173 (47.7%) for 99mTC alone. The para-aortic mapping rate was 18 (3.4%) for ICG group, 38 (11.5%) for ICG + 99mTC and 25 (6.9%) for 99mTC alone, respectively (p< 0.001). Empty node packets were diagnosed only in 10 (1.6%) patients of the ICG group (p <0.001). The sensitivity was: 77% for ICG group, 90% for ICG + 99mTC and 97% for 99mTC alone. The false negative rate was 23% for the ICG group, 9,5% for ICG + 99mTC group and 3,3% 99mTC alone group.

Univariate and multivariate analysis showed that age, uterus site of injection and the use of ICG + 99mTC were independent predictive factors of bilateral drainage.

Abstract 2022-RA-1250-ESGO Table 1

Patient demographics and sentinel lymph node biopsy characteristics

Abstract 2022-RA-1250-ESGO Table 2

Multivariate analysis: bilateral drainage

Conclusion We did not find any differences among tracers in terms of accuracy; Otherwise, combining 99mTc to ICG achieves the highest overall and bilateral detection rates.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.